Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial

Key Takeaways

• Shares of Novartis declined more than 3% on Monday following negative results from a pivotal cardiovascular study
• The Lp(a)HORIZON study enrolled over 8,000 participants but failed to demonstrate reduced cardiovascular events as its primary endpoint
• While pelacarsen successfully reduced lipoprotein(a) levels in the blood, this reduction didn’t prevent heart attacks, strokes, or cardiovascular fatalities
• The disappointing outcome casts doubt on competing Lp(a)-targeted therapies being developed by Amgen and Eli Lilly through alternative mechanisms
• Year-to-date, Novartis shares have gained 14%, reflecting Monday’s decline from previously stronger performance

Novartis stock tumbled over 3% during European market hours on Monday following the pharmaceutical giant’s announcement that pelacarsen, its investigational cardiovascular therapy, missed its primary endpoint in a significant late-stage clinical study. The decline trimmed the company’s year-to-date stock appreciation to approximately 14%.

Novartis AG, NVS

The study at the center of this setback is known as Lp(a)HORIZON, a large-scale clinical investigation that recruited over 8,000 participants with heightened lipoprotein(a) concentrations, a lipid particle associated with increased cardiovascular disease risk.

While pelacarsen demonstrated efficacy in reducing Lp(a) concentrations in the bloodstream, this biochemical improvement failed to produce meaningful reductions in cardiovascular events such as myocardial infarctions, cerebrovascular accidents, or mortality.

This disconnect between biomarker modification and clinical benefit represents a significant challenge for any therapeutic candidate.

Shreeram Aradhye, Novartis’s Chief Medical Officer, expressed disappointment with the findings, stating the outcome was “not what we hoped for,” while noting that the data nonetheless contributes valuable insights into how Lp(a) reduction correlates with cardiovascular risk reduction.

Implications for Competing Therapies

The ramifications extend beyond Novartis alone. Both Amgen and Eli Lilly have Lp(a)-targeting candidates in development, although they employ different biological mechanisms. Pelacarsen’s failure prompts questions about whether simply reducing Lp(a) levels is sufficient to confer cardiovascular protection.

To date, no therapy specifically designed to lower lipoprotein(a) has received regulatory approval, despite elevated Lp(a) concentrations affecting approximately 20% of the global population.

Novartis licensed pelacarsen from Ionis Pharmaceuticals. The drug operates as an antisense oligonucleotide, a mechanism that inhibits Lp(a) production at the molecular level.

Increasing Pipeline Scrutiny

Jefferies analysts observed that the continued success of established cardiovascular medications, coupled with the emergence of GLP-1 receptor agonists for weight management, has elevated expectations for novel cardiac therapies to demonstrate clear clinical benefits in outcomes studies.

This trial disappointment arrives just days after Novartis suspended eight clinical studies of an experimental cell-based treatment for autoimmune and neurological conditions following three patient fatalities.

According to Jefferies, encouraging data from a recent multiple sclerosis study should provide some reassurance to shareholders.

However, the firm also highlighted that Novartis faces mounting expectations to generate favorable data from a therapy obtained through its $12 billion acquisition of Avidity Biosciences to validate that substantial investment.

Complete findings from the Lp(a)HORIZON trial will be disclosed at an upcoming medical conference.

The post Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial appeared first on Blockonomi.